Quarterly ResultMay 12, 2026, 07:02 AM
ProQR Q1 2026 Net Loss €13.4M; AX-0810 Data on Track for Q2 2026
AI Summary
ProQR Therapeutics reported its first-quarter 2026 operating and financial results, with a net loss of €13.4 million and cash and cash equivalents of €81.1 million, providing a runway into mid-2027. The company is on track to report AX-0810 target engagement data in Q2 2026 and has selected biliary atresia as the initial Phase 2 indication, with an investigator-initiated trial in China targeting H1 2027 data. ProQR also announced pipeline expansion with AX-0811 and AX-0422 advancing toward the clinic, and continued development of its Axiomer platform, including an AI partnership with Ginkgo Bioworks.
Key Highlights
- AX-0810 target engagement data in healthy volunteers on track for Q2 2026.
- AX-0810 Phase 2 initial indication changed to biliary atresia, with IIT data targeted for H1 2027.
- AX-0811 CTA filing expected mid-2026, with initial clinical data by year-end 2026.
- AX-0422 CTA filing expected early 2027, with initial clinical data targeted for H1 2027.
- Ended Q1 2026 with €81.1 million in cash and cash equivalents, supporting runway into mid-2027.
- Net loss for Q1 2026 was €13.4 million, or €0.13 per diluted share.
- Net cash used in operating activities for Q1 2026 was €11.1 million, down from €15.8 million in Q1 2025.
- R&D costs for Q1 2026 were €11.8 million, compared to €12.3 million in Q1 2025.